Nowe trendy w farmakoterapii jaskry
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2019
Słowa kluczowe:
jaskra, inhibitory kinazy Rha, netarsudil, latanaprost bunad, neuropratekcja, cytykalina
##plugins.themes.bootstrap3.article.main##
Abstrakt
Pomimo licznych metod leczenia jaskry nadal nie potrafimy wpływać na wszystkie przyczyny jej powstawania. Dlatego badane są liczne substancje o różnych mechanizmach działania. W ostatnim czasie zostały wprowadzone do lecznictwa 3 leki: cytykolina, netarsudil i latanoprost bunod, które zostaną omówione w tym artykule.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Szumny D. Nowe trendy w farmakoterapii jaskry. Ophthatherapy [Internet]. 31 marzec 2019 [cytowane 3 lipiec 2024];6(1):26-9. Dostępne na: https://journalsmededu.pl/index.php/ophthatherapy/article/view/506
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Yang X, Zeng Q, Goktas E et al. T-Lymphocyte Subset Distribution and Activity in Patients with Glaucoma. Invest Ophthalmol Vis Sci. 2019; 60(4): 877-88.
2. Bucolo C, Platania CBM, Drago F et al. Novel Therapeutics in Glaucoma Management. Curr Neuropharmacol. 2018; 16(7): 978-92.
3. Fingeret M, Gaddie IB, Bloomenstein M. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension. Clin Exp Optom. 2019. https://doi.org/10.1111/cxo.12853.
4. Khouri AS, Serle JB, Bacharach J et al. Once-Daily Netarsudil vs Twice-Daily Timolol in Patients with Elevated Intraocular Pressure, the Randomized Phase 3 ROCKET-4 Study. Am J Ophthalmol. 2019. https://doi.org/10.1016/j.ajo.2019.03.002.
5. Kahook MY, Serle JB, Mach FS et al. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution. Am J Ophthalmol. 2019. https://doi.org/10.1016/j.ajo.2019.01.003.
6. You Y, Joseph C, Wang C et al. Demyelination precedes axonal loss in the transneuronal spread of human neurodegenerative disease. Brain. 2019; 142(2): 426-42.
7. Boyd ZS, Kriatchko A, Yang J et al. Interleukin-10 receptor signaling through STAT-3 regulates the apoptosis of retinal ganglion cells in response to stress. Invest Ophthalmol Vis Sci. 2003; 44(12): 5206-11.
8. Schmidl D, Schmetterer L, Garhöfer G et al. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015; 31(2): 63-77.
9. McKinnon SJ, Lehman DM, Tahzib NG et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther. 2002; 5(6): 780-7.
10. Tomita H., Nakazawa T, Sugano E et al. Nipradilol inhibits apoptosis by preventing the activation of caspase-3 via S-nitrosylation and the cGMP-dependent pathway. Eur J Pharmacol. 2002; 452(3): 263-8.
11. Tsai JC, Song BJ, Wu L et al. Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma. 2007; 16(6): 567-71.
12. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res. 2002; 70(2): 133-9.
13. Parisi V, Oddone F, Ziccardi L et al. Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function. Curr Neuropharmacol. 2018; 16(7): 919-32.
14. Parisi V, Oddone F, Roberti G. Enhancement of Retinal Function and of Neural Conduction Along the Visual Pathway Induced by Treatment with Citicoline Eye Drops in Liposomal Formulation in Open Angle Glaucoma: A Pilot Electrofunctional Study. Adv Ther. 2019. https://doi.org/10.1007/s12325-019-0897-z.
15. Adams CM, Stacy R, Rangaswamy N et al. Glaucoma – Next Generation Therapeutics: Impossible to Possible. Pharm Res. 2018; 36(2): 25.
16. Dillinger AE, Guter M, Froemel F et al. Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy. Small. 2018; 14(50): e1803239.
2. Bucolo C, Platania CBM, Drago F et al. Novel Therapeutics in Glaucoma Management. Curr Neuropharmacol. 2018; 16(7): 978-92.
3. Fingeret M, Gaddie IB, Bloomenstein M. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension. Clin Exp Optom. 2019. https://doi.org/10.1111/cxo.12853.
4. Khouri AS, Serle JB, Bacharach J et al. Once-Daily Netarsudil vs Twice-Daily Timolol in Patients with Elevated Intraocular Pressure, the Randomized Phase 3 ROCKET-4 Study. Am J Ophthalmol. 2019. https://doi.org/10.1016/j.ajo.2019.03.002.
5. Kahook MY, Serle JB, Mach FS et al. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution. Am J Ophthalmol. 2019. https://doi.org/10.1016/j.ajo.2019.01.003.
6. You Y, Joseph C, Wang C et al. Demyelination precedes axonal loss in the transneuronal spread of human neurodegenerative disease. Brain. 2019; 142(2): 426-42.
7. Boyd ZS, Kriatchko A, Yang J et al. Interleukin-10 receptor signaling through STAT-3 regulates the apoptosis of retinal ganglion cells in response to stress. Invest Ophthalmol Vis Sci. 2003; 44(12): 5206-11.
8. Schmidl D, Schmetterer L, Garhöfer G et al. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015; 31(2): 63-77.
9. McKinnon SJ, Lehman DM, Tahzib NG et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther. 2002; 5(6): 780-7.
10. Tomita H., Nakazawa T, Sugano E et al. Nipradilol inhibits apoptosis by preventing the activation of caspase-3 via S-nitrosylation and the cGMP-dependent pathway. Eur J Pharmacol. 2002; 452(3): 263-8.
11. Tsai JC, Song BJ, Wu L et al. Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma. 2007; 16(6): 567-71.
12. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res. 2002; 70(2): 133-9.
13. Parisi V, Oddone F, Ziccardi L et al. Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function. Curr Neuropharmacol. 2018; 16(7): 919-32.
14. Parisi V, Oddone F, Roberti G. Enhancement of Retinal Function and of Neural Conduction Along the Visual Pathway Induced by Treatment with Citicoline Eye Drops in Liposomal Formulation in Open Angle Glaucoma: A Pilot Electrofunctional Study. Adv Ther. 2019. https://doi.org/10.1007/s12325-019-0897-z.
15. Adams CM, Stacy R, Rangaswamy N et al. Glaucoma – Next Generation Therapeutics: Impossible to Possible. Pharm Res. 2018; 36(2): 25.
16. Dillinger AE, Guter M, Froemel F et al. Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy. Small. 2018; 14(50): e1803239.